Lexeo Therapeutics Statistics
Total Valuation
LXEO has a market cap or net worth of $332.92 million. The enterprise value is $168.80 million.
Important Dates
The next estimated earnings date is Thursday, November 21, 2024, after market close.
| Earnings Date | Nov 21, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LXEO has 33.06 million shares outstanding. The number of shares has increased by 1,114.55% in one year.
| Shares Outstanding | 33.06M |
| Shares Change (YoY) | +1,114.55% |
| Shares Change (QoQ) | +17.95% |
| Owned by Insiders (%) | 4.43% |
| Owned by Institutions (%) | 50.70% |
| Float | 16.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.02 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.38, with a Debt / Equity ratio of 0.07.
| Current Ratio | 9.38 |
| Quick Ratio | 9.27 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -471.77 |
Financial Efficiency
Return on equity (ROE) is -74.83% and return on invested capital (ROIC) is -44.64%.
| Return on Equity (ROE) | -74.83% |
| Return on Assets (ROA) | -39.93% |
| Return on Capital (ROIC) | -44.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.33M |
| Employee Count | 58 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 10.19 |
| 200-Day Moving Average | 13.59 |
| Relative Strength Index (RSI) | 54.65 |
| Average Volume (20 Days) | 335,648 |
Short Selling Information
The latest short interest is 2.07 million, so 6.27% of the outstanding shares have been sold short.
| Short Interest | 2.07M |
| Short Previous Month | 1.19M |
| Short % of Shares Out | 6.27% |
| Short % of Float | 12.21% |
| Short Ratio (days to cover) | 5.89 |
Income Statement
| Revenue | n/a |
| Gross Profit | -57.76M |
| Operating Income | -82.09M |
| Pretax Income | -69.42M |
| Net Income | -77.22M |
| EBITDA | -81.46M |
| EBIT | -82.09M |
| Earnings Per Share (EPS) | -$3.90 |
Full Income StatementBalance Sheet
The company has $174.98 million in cash and $10.85 million in debt, giving a net cash position of $164.13 million or $4.96 per share.
| Cash & Cash Equivalents | 174.98M |
| Total Debt | 10.85M |
| Net Cash | 164.13M |
| Net Cash Per Share | $4.96 |
| Equity (Book Value) | 164.95M |
| Book Value Per Share | 4.99 |
| Working Capital | 158.27M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$62.95 million and capital expenditures -$474,000, giving a free cash flow of -$63.42 million.
| Operating Cash Flow | -62.95M |
| Capital Expenditures | -474,000 |
| Free Cash Flow | -63.42M |
| FCF Per Share | -$1.92 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |